Plavix
Sanofi lowers Q3 sales figures from 2015
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results
Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …
NICE extends recommendation for Efient
July 24, 2014Sales and Marketing ACS, Efient, NICE, Plavix, longs ton, prasugrel
In updated guidance NICE has extended its recommendation of Efient (prasugrel) in combination with aspirin for preventing blood clots in …
CHMP approves six drugs including daclatasvir
June 30, 2014Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge
A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …
BMS hopes for Yervoy sequel with new deal
March 18, 2014Research and Development, Sales and Marketing Avapro, BMS, Plavix, Yervoy, five prime, immune-oncology
Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …
Analysts ‘disappointed’ by Sanofi guidance
February 6, 2014Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales
Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …
Sanofi sales slide on patent cliff woes
August 1, 2013Sales and Marketing Aprovel, Plavix, Q2, Sanofi
Sanofi has been hit by generic erosion for key drugs in the second quarter, but the firm is confident it …
Sharp fall in sales for Bristol-Myers Squibb
July 26, 2013Sales and Marketing Avapro, BMS, Plavix, Q2
Bristol-Myers Squibb has seen a fall in sales over the past three months as it struggles with major patent losses. …
Diabetes softens generics blow for Sanofi
October 30, 2012Sales and Marketing Eloxatin, Plavix, Sanofi, diabetes, emerging markets, patent cliff
Sanofi has unveiled its results for the third quarter, with news that the damage done by patent expiries has not …
Patent losses force change for Sanofi
October 3, 2012Sales and Marketing Avapro, BMS, Plavix, Sanofi, patent loss
Patent expiries are behind the decision by Sanofi and Bristol-Myers Squibb to radically restructure their long-term corporate alliance. The loss …
Pharma is recovering, says Moody’s
September 25, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Moody's, Plavix, austerity, generics, pharma
Credit ratings agency Moody’s believes that the travails of the past few years, when various big-selling drugs went off-patent, are …
Efient fails to prove superiority to Plavix
August 29, 2012Brillinta, Efient, Plavix, prasugrel, ticagrelor
Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
Dismay as Sanofi announces UK plant closure
March 15, 2012Manufacturing and Production, Sales and Marketing Plavix, Sanofi, job losses, manufacturing
Sanofi has decided to close down a manufacturing facility in the North East of the UK with the loss of …
Brilique recommended for use by Germany’s pricing watchdog
December 19, 2011Sales and Marketing AstraZeneca, Brilique, Plavix
Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
Latest content
Artificial hearts: a century of innovation
